



## Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications May 2020 CPT® Editorial Panel Meeting

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications (CCAs) that have been submitted for consideration by the CPT Editorial Panel at its May 2020 meeting are listed below. These applications will also be included in the proposed Panel agenda that will be posted to the AMA website on March 13, 2020. This listing includes the code application names, code(s) affected, and a description of the request. **Until such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).**

This listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP applications is being posted ahead of the full May Panel meeting agenda in order to provide the Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested stakeholders prior to making their recommendations to the CPT Editorial Panel.

Codes that contain an 'X' (e.g., 10X24, 23X42, 03X01T) below are temporary codes that are intended to give readers an idea of the proposed placement in the code set of the potential code changes. **These temporary codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31<sup>st</sup> of each year. To report the services described by the "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31<sup>st</sup> of the corresponding year.**

Upon review of these applications, if the reviewer believes that they will need to provide comment on an issue, they should send a request for a copy of the application and associated materials to [Michael Pellegrino](#). This request for review of the agenda materials should contain the identity of the interested party seeking such and a brief summary of the basis for the request (e.g., associated vendor/ industry representative).

Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code change application is automatically considered an interested party and is notified by AMA staff of any request for review submitted by another party.

\*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and disclosure of interest form.

Updated February 20, 2020

- New
- ▲ Revision
- + Add on
- D Deletion



Please follow the instructions in the correspondence that accompanies the materials.

Pathology/Laboratory and Molecular Pathology, Multianalyte Assays with Algorithmic Analyses, and Genomic Sequencing Procedures Deadlines for Interested Stakeholders	
<b>Request for Code Change Application Materials</b>	<b>February 26</b>
<b>Submission of Written Comments</b>	<b>March 2</b>

During the time between now and the Panel meeting, this listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP CCAs may be modified to reflect changes – additions, deletions or updates. Please check back frequently for the most up to date information. Outcomes on these actions will be listed in the CPT Editorial Panel Summary of Actions for the May 2020 meeting, which will be published on or before June 15, 2020 to the CPT home page of the AMA website <http://www.ama-assn.org/go/panel-actions>.

Tab #	Name	Code #	Request-Description
22	Carbamazepine 10 11-Epoxy Ther Drug Assay	● 80XX3	Establish code 80XX3 for Carbamazepine 10 11-Epoxy therapeutic drug assay
23	Felbamate Ther Drug Assay	● 80XX4	Establish code 80XX4 for Felbamate therapeutic drug assay

Updated February 20, 2020

- New
- ▲ Revision
- + Add on
- D Deletion

Tab #	Name	Code #	Request-Description
24	Flecainide Ther Drug Assay	● 80XX5	Establish code 80XX5 for Flecainide therapeutic drug assay
25	Itraconazole Ther Drug Assay	● 80XX6	Establish code 80XX6 for Itraconazole therapeutic drug assay
26	Leflunomide Ther Drug Assay	● 80XX7	Establish code 80XX7 for Leflunomide therapeutic drug assay
27	Methotrexate Ther Drug Assay	● 80XX8	Establish code 80XX8 for Methotrexate therapeutic drug assay
28	Rufinamide Ther Drug Assay	● 802XX	Establish code 802XX for Rufinamide therapeutic drug assay
29	Admin MAAA Adrenal Cortex	● 003XM	Establish Administrative MAAA code 003XM for MAAA test for risk of malignancy of adrenal cortex lesion
30	MAAA Breast Cancer Metastasis Risk	▲ 81521 ● 815X1	Revise MAAA code 81521 to describe mRNA microarray or next generation sequencing gene expression profiling of 70 content genes and 465 or 31 housekeeping genes for distant metastasis risk OR Establish new code 815X1 for MAAA test for mRNA next generation sequencing gene expression profiling of 70 content genes and 31 housekeeping genes for distant metastasis risk

Updated February 20, 2020

● New  
▲ Revision  
+ Add on  
D Deletion

Tab #	Name	Code #	Request-Description
31	MAAA Bladder Cancer Genomic Subtyping Classifier	● 815X2	Establish code 815X2 for MAAA test for molecular subtype-muscular invasive bladder cancer
32	MAAA Bacterial Vaginosis	● 815X3	Establish code 815X3 for MAAA test for bacterial vaginosis positive or negative result
33	MAAA Allograft Rejection Risk	● 815X4	Establish code 815X4 for MAAA test for allograft rejection risk
34	GSP Targeted Panel-Solid Tumor	▲ 81445 ▲ 81455 ● 814XX	Revise GSP codes 81445 and 81455 by removing RNA analysis and establish GSP code 814XX for targeted fusion RNA analysis panel for solid organ neoplasm
35	Cat III 0500T to Cat I HPV Genotyping	D0500T ● 876XX	Delete Category III code 0500T for Infectious agent detection for HPV and establish Category I code 8762X
36	Campylobacter-4 Species Infectious Agent Antigen Detection	● 82XX0	Establish code 82XX0 for detection of campylobacter antigens
37	Free Estradiol Measurement Testing	▲ 80415 ▲ 82670 ● 82XX1	Revise estradiol response code 80415 to specify total estradiol response, revise estradiol chemistry code 82670 to specify total estradiol measurement and establish chemistry code 82XX1 for estradiol, free, direct measurement (eg, equilibrium dialysis)